

# **Workshop on Adjuvants and Formulation of HIV-1 Env Vaccines**

**Chaired by Nathalie Garçon and Robert Seder**

**Sponsored by the Division of AIDS/NIAID/NIH,  
Bill & Melinda Gates Foundation and the Global HIV Vaccine Enterprise**

**July 9<sup>th</sup> 2014, 8am to 5pm**

**Balcony "B" Natcher Center – NIH Campus – Bethesda, MD**

**8:00 – 8:15am – Welcome and objectives of the workshop**

Workshop chairs: **Nathalie Garçon and Robert Seder**

**8:15 – 8:45am – HIV-1 Env Structure and Antigenic Properties**

Peter Kwong (VRC/NIH)

**8:45 – 9:15am – Desired immune Responses and Clinical Adjuvant Landscape**

Julie McElrath (HVTN/ FHCRC/University of Washington)

**9:15 – 10:15am – Immunological Adjuvant Selection and Evaluation I**

Session Chair: **Robert Seder**

Panelists: Arnaud Didierlaurent (GSK)  
Steve Reed (IDRI)  
Heather Davis (Pfizer)  
Carl Alving (MHRP)  
Robert Coffman (Dynavax)  
Debbie Drane (CSL)

**10:15 – 10:35am – Coffee break**

**10:35 – 11:35am – Immunological Adjuvant Selection and Evaluation II**

Session Chair: **Robert Seder**

Panelists: Robert Seder (VRC – NIH)  
Bali Pulendran (Emory University)  
Galit Alter (Ragon Institute – Harvard)  
George Lewis (University of Maryland)

**11:35 – 12:30pm – Adjuvant Formulation and Product Characterization I**

Session Chair: **Nathalie Garçon**

Panelists: Dennis Christensen (Statens Serum Institute)  
David Volkin (Kansas University)  
Darrel Irvine (MIT)  
Munir Alam (Duke University)

**12:30 – 1:30pm – Lunch**

**1:30 – 2:30pm – Adjuvant formulation and Product Characterization II**

Session Chair: **Nathalie Garçon**

*Conference attendees and/or presenters are responsible for meals and/or light refreshments on their own and at their own cost. Government staff and/or Government contractors may not be involved in the provision or facilitation of food and/or light refreshments for conference attendees and/or presenters.*

Panelists: Nathalie Garçon (BIOASTER)  
Jean Haensler (Sanofi)  
Antu Dey (Novartis)

2:30 – 3:45pm – **Regulatory considerations and studies required to initiate Phase 1 studies**

Chair: Elizabeth Sutkowski (FDA)  
Panelists: Elizabeth Sutkowski (FDA)  
Hana Golding (FDA)  
María Baca-Estrada (Health Canada)  
Nathalie Garçon (BIOASTER)

3:45 – 4:05pm – **Coffee break**

4:05 – 4:45pm – **Closing statements and action items**

Workshop chairs: **Nathalie Garçon and Robert Seder**